Global Pulmonary Arterial Hypertension (PAH) Market Report 2021
Global Pulmonary Arterial Hypertension (PAH) Market Report 2021
The Global Pulmonary Arterial Hypertension (PAH) Market investigation report contains Types, Application & all logical and factual briefs about market Overview, CAGR, Production Volume, Sales, Revenue with the regional analysis covers North America, Europe, Asia-Pacific, South America, Middle East & Africa & The top Players like Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer, Arena
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
At the beginning of 2020, COVID-19 disease began to spread around the world, millions of people worldwide were infected with COVID-19 disease, and major countries around the world have implemented foot prohibitions and work stoppage orders. Except for the medical supplies and life support products industries, most industries have been greatly impacted, and Pulmonary Arterial Hypertension (PAH) industries have also been greatly affected.
In the past few years, the Pulmonary Arterial Hypertension (PAH) market experienced a growth of xx, the global market size of Pulmonary Arterial Hypertension (PAH) reached xx million $ in 2020, of what is about xx million $ in 2015.
From 2015 to 2019, the growth rate of global Pulmonary Arterial Hypertension (PAH) market size was in the range of xxx%. At the end of 2019, COVID-19 began to erupt in China, Due to the huge decrease of global economy; we forecast the growth rate of global economy will show a decrease of about 4%, due to this reason, Pulmonary Arterial Hypertension (PAH) market size in 2020 will be xx with a growth rate of xxx%. This is xxx percentage points lower than in previous years.
As of the date of the report, there have been more than 20 million confirmed cases of CVOID-19 worldwide, and the epidemic has not been effectively controlled. Therefore, we predict that the global epidemic will be basically controlled by the end of 2020 and the global Pulmonary Arterial Hypertension (PAH) market size will reach xx million $ in 2025, with a CAGR of xxx% between 2020-2025.
This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.
Section 1: Free——Definition
Section (2 3): 1200 USD——Manufacturer Detail
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
Section 4: 900 USD——Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7): 500 USD——
Product Type Segmentation
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Industry Segmentation
Hospital
Clinic
Channel (Direct Sales, Distributor) Segmentation
Section 8: 400 USD——Trend (2020-2025)
Section 9: 300 USD——Product Type Detail
Section 10: 700 USD——Downstream Consumer
Section 11: 200 USD——Cost Structure
Section 12: 500 USD——Conclusion
Section 1 Pulmonary Arterial Hypertension (PAH) Product Definition
Section 2 Global Pulmonary Arterial Hypertension (PAH) Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Pulmonary Arterial Hypertension (PAH) Shipments
2.2 Global Manufacturer Pulmonary Arterial Hypertension (PAH) Business Revenue
2.3 Global Pulmonary Arterial Hypertension (PAH) Market Overview
2.4 COVID-19 Impact on Pulmonary Arterial Hypertension (PAH) Industry
Section 3 Manufacturer Pulmonary Arterial Hypertension (PAH) Business Introduction
3.1 Actelion Pulmonary Arterial Hypertension (PAH) Business Introduction
3.1.1 Actelion Pulmonary Arterial Hypertension (PAH) Shipments, Price, Revenue and Gross profit 2015-2020
3.1.2 Actelion Pulmonary Arterial Hypertension (PAH) Business Distribution by Region
3.1.3 Actelion Interview Record
3.1.4 Actelion Pulmonary Arterial Hypertension (PAH) Business Profile
3.1.5 Actelion Pulmonary Arterial Hypertension (PAH) Product Specification
3.2 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Business Introduction
3.2.1 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Shipments, Price, Revenue and Gross profit 2015-2020
3.2.2 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Business Distribution by Region
3.2.3 Interview Record
3.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Business Overview
3.2.5 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product Specification
3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Business Introduction
3.3.1 United Therapeutics Pulmonary Arterial Hypertension (PAH) Shipments, Price, Revenue and Gross profit 2015-2020
3.3.2 United Therapeutics Pulmonary Arterial Hypertension (PAH) Business Distribution by Region
3.3.3 Interview Record
3.3.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Business Overview
3.3.5 United Therapeutics Pulmonary Arterial Hypertension (PAH) Product Specification
3.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Business Introduction
3.5 Pfizer Pulmonary Arterial Hypertension (PAH) Business Introduction
3.6 Bayer Pulmonary Arterial Hypertension (PAH) Business Introduction
…
Section 4 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Region Level)
4.1 North America Country
4.1.1 United States Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.1.2 Canada Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.2 South America Country
4.2.1 South America Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.3 Asia Country
4.3.1 China Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.3.2 Japan Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.3.3 India Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.3.4 Korea Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.4 Europe Country
4.4.1 Germany Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.4.2 UK Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.4.3 France Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.4.4 Italy Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.4.5 Europe Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.5 Other Country and Region
4.5.1 Middle East Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.5.2 Africa Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.5.3 GCC Pulmonary Arterial Hypertension (PAH) Market Size and Price Analysis 2015-2020
4.6 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Region Level) Analysis 2015-2020
4.7 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Region Level) Analysis
Section 5 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Product Type Level)
5.1 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Product Type Level) Market Size 2015-2020
5.2 Different Pulmonary Arterial Hypertension (PAH) Product Type Price 2015-2020
5.3 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Product Type Level) Analysis
Section 6 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Industry Level)
6.1 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Industry Level) Market Size 2015-2020
6.2 Different Industry Price 2015-2020
6.3 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Industry Level) Analysis
Section 7 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Channel Level)
7.1 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Channel Level) Sales Volume and Share 2015-2020
7.2 Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Channel Level) Analysis
Section 8 Pulmonary Arterial Hypertension (PAH) Market Forecast 2020-2025
8.1 Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Region Level)
8.2 Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Product Type Level)
8.3 Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Industry Level)
8.4 Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Channel Level)
Section 9 Pulmonary Arterial Hypertension (PAH) Segmentation Product Type
9.1 Prostacyclin and Prostacyclin Analogs Product Introduction
9.2 SGC Stimulators Product Introduction
9.3 ERA Product Introduction
9.4 PDE-5 Product Introduction
Section 10 Pulmonary Arterial Hypertension (PAH) Segmentation Industry
10.1 Hospital Clients
10.2 Clinic Clients
Section 11 Pulmonary Arterial Hypertension (PAH) Cost of Production Analysis
11.1 Raw Material Cost Analysis
11.2 Technology Cost Analysis
11.3 Labor Cost Analysis
11.4 Cost Overview
Section 12 Conclusion
Chart and Figure
Figure Pulmonary Arterial Hypertension (PAH) Product Picture from Actelion
Chart 2015-2020 Global Manufacturer Pulmonary Arterial Hypertension (PAH) Shipments (Units)
Chart 2015-2020 Global Manufacturer Pulmonary Arterial Hypertension (PAH) Shipments Share
Chart 2015-2020 Global Manufacturer Pulmonary Arterial Hypertension (PAH) Business Revenue (Million USD)
Chart 2015-2020 Global Manufacturer Pulmonary Arterial Hypertension (PAH) Business Revenue Share
Chart Actelion Pulmonary Arterial Hypertension (PAH) Shipments, Price, Revenue and Gross profit 2015-2020
Chart Actelion Pulmonary Arterial Hypertension (PAH) Business Distribution
Chart Actelion Interview Record (Partly)
Figure Actelion Pulmonary Arterial Hypertension (PAH) Product Picture
Chart Actelion Pulmonary Arterial Hypertension (PAH) Business Profile
Table Actelion Pulmonary Arterial Hypertension (PAH) Product Specification
Chart Gilead Sciences Pulmonary Arterial Hypertension (PAH) Shipments, Price, Revenue and Gross profit 2015-2020
Chart Gilead Sciences Pulmonary Arterial Hypertension (PAH) Business Distribution
Chart Gilead Sciences Interview Record (Partly)
Figure Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product Picture
Chart Gilead Sciences Pulmonary Arterial Hypertension (PAH) Business Overview
Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product Specification
Chart United Therapeutics Pulmonary Arterial Hypertension (PAH) Shipments, Price, Revenue and Gross profit 2015-2020
Chart United Therapeutics Pulmonary Arterial Hypertension (PAH) Business Distribution
Chart United Therapeutics Interview Record (Partly)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Product Picture
Chart United Therapeutics Pulmonary Arterial Hypertension (PAH) Business Overview
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Product Specification
3.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Business Introduction
…
Chart United States Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart United States Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Canada Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Canada Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart South America Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart South America Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart China Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart China Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Japan Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Japan Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart India Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart India Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Korea Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Korea Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Germany Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Germany Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart UK Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart UK Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart France Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart France Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Italy Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Italy Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Europe Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Europe Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Middle East Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Middle East Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Africa Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart Africa Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart GCC Pulmonary Arterial Hypertension (PAH) Sales Volume (Units) and Market Size (Million $) 2015-2020
Chart GCC Pulmonary Arterial Hypertension (PAH) Sales Price ($/Unit) 2015-2020
Chart Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Region Level) Sales Volume 2015-2020
Chart Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Region Level) Market size 2015-2020
Chart Pulmonary Arterial Hypertension (PAH) Market Segmentation (Product Type Level) Volume (Units) 2015-2020
Chart Pulmonary Arterial Hypertension (PAH) Market Segmentation (Product Type Level) Market Size (Million $) 2015-2020
Chart Different Pulmonary Arterial Hypertension (PAH) Product Type Price ($/Unit) 2015-2020
Chart Pulmonary Arterial Hypertension (PAH) Market Segmentation (Industry Level) Market Size (Volume) 2015-2020
Chart Pulmonary Arterial Hypertension (PAH) Market Segmentation (Industry Level) Market Size (Share) 2015-2020
Chart Pulmonary Arterial Hypertension (PAH) Market Segmentation (Industry Level) Market Size (Value) 2015-2020
Chart Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Channel Level) Sales Volume (Units) 2015-2020
Chart Global Pulmonary Arterial Hypertension (PAH) Market Segmentation (Channel Level) Share 2015-2020
Chart Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Region Level) 2020-2025
Chart Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Product Type Level) 2020-2025
Chart Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Industry Level) 2020-2025
Chart Pulmonary Arterial Hypertension (PAH) Segmentation Market Forecast (Channel Level) 2020-2025
Chart Prostacyclin and Prostacyclin Analogs Product Figure
Chart Prostacyclin and Prostacyclin Analogs Product Advantage and Disadvantage Comparison
Chart SGC Stimulators Product Figure
Chart SGC Stimulators Product Advantage and Disadvantage Comparison
Chart ERA Product Figure
Chart ERA Product Advantage and Disadvantage Comparison
Chart PDE-5 Product Figure
Chart PDE-5 Product Advantage and Disadvantage Comparison
Chart Hospital Clients
Chart Clinic Clients
Research Methodology:
Pulmonary Arterial Hypertension (PAH) Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|